IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 70.49

Change

+0.14 (+0.20)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-12 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.21 (-0.14%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

-0.04 (-0.06%)

USD 2.66B
FXH First Trust Health Care AlphaD..

-0.73 (-0.68%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-1.13 (-1.23%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.20 (+0.90%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.39 (+1.23%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-0.33 (-0.33%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.06 (+0.20%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.44 (+0.72%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.34 (+1.61%)

USD 6.89M

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.26% 86% B+ 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.26% 86% B+ 83% B
Trailing 12 Months  
Capital Gain 4.90% 67% D+ 48% F
Dividend Return 1.38% 88% B+ 23% F
Total Return 6.28% 67% D+ 40% F
Trailing 5 Years  
Capital Gain 31.19% 67% D+ 65% D
Dividend Return 8.81% 95% A 27% F
Total Return 40.00% 76% C+ 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 4.17% 48% F 48% F
Dividend Return 5.56% 57% F 45% F
Total Return 1.39% 100% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 15.35% 71% C- 66% D+
Risk Adjusted Return 36.23% 67% D+ 50% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike